BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/23/2015 3:58:00 PM | Browse: 1483 | Download: 2686
 |
Received |
|
2015-05-04 16:51 |
 |
Peer-Review Started |
|
2015-05-09 15:54 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2015-06-09 12:44 |
 |
Revised |
|
2015-06-17 00:00 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2015-08-06 21:21 |
 |
Second Decision by Editor-in-Chief |
|
2015-08-07 01:07 |
 |
Final Decision by Editorial Office Director |
|
2015-08-31 17:54 |
 |
Articles in Press |
|
2015-08-31 17:54 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2015-10-12 17:50 |
 |
Publish the Manuscript Online |
|
2015-10-23 15:45 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reaction
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Masahiro Tanemura, Eiji Miyoshi, Hiroaki Nagano, Hidetoshi Eguchi, Katsuyoshi Matsunami, Kiyomi Taniyama, Nobutaka Hatanaka, Hiroki Akamatsu, Masaki Mori and Yuichiro Doki |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministry of Education, Sports and Culture of Japan |
25462129(to M. T.) |
|
| Corresponding Author |
Masahiro Tanemura, MD, PhD, Department of Surgery, Osaka Police Hospital, 10-31 Kitayamacho Tennoujiku, Osaka 543-0035, Japan. tanemuram@oph.gr.jp
|
| Key Words |
Pancreatic cancer; Immunotherapy; Cancer antigen; MUC1; α-gal epitopes; Cancer vaccine; Cancer stem cell; Carbohydrate research |
| Core Tip |
The goal of cancer immunotherapy is to elicit an immune response against autologous tumors and to induce multiple T cell clones against multiple tumor-associated antigens. To establish effective, next-generation immunotherapy toward pancreatic ductal adenocarcinoma (PDAC), we focus on the strong interaction between the natural human antibody, anti-Gal, and carbohydrate antigens called “α-gal epitopes”. Here, we review the literature on the distribution of natural anti-Gal antibody and its ligand in mammals and characterization of the immunosuppressive microenvironment of PDAC tumors, which is a major obstacle against effective clinical immunotherapies. We also discuss immunotherapeutic strategies using the α-gal epitope/anti-Gal antibody reaction.
|
| Publish Date |
2015-10-23 15:45 |
| Citation |
Tanemura M, Miyoshi E, Nagano H, Eguchi H, Matsunami K, Taniyama K, Hatanaka N, Akamatsu H, Mori M, Doki Y. Cancer immunotherapy for pancreatic cancer utilizing -gal epitope/natural anti-Gal antibody reaction. World J Gastroenterol 2015; 21(40): 11396-11410 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i40/11396.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i40.11396 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.